These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6414212)

  • 1. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B.
    Branson HE; Schmer G; Theodor I; Pirkle H
    Acta Haematol; 1983; 70(4):257-63. PubMed ID: 6414212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen Seattle II: defective release of fibrinopeptide A in a slow clotting fibrinogen.
    Schreiber WE; Schmer G
    Thromb Res; 1985 Jan; 37(1):45-52. PubMed ID: 3983901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution.
    Ebert RF; Schreiler WE; Bell WR
    Thromb Res; 1986 Jul; 43(1):7-13. PubMed ID: 3726812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
    Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
    Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen Aarhus--a new case of dysfibrinogenemia.
    Hessel B; Stenbjerg S; Dyr J; Kudryk B; Therkildsen L; Blombäck B
    Thromb Res; 1986 Apr; 42(1):21-37. PubMed ID: 2939591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues.
    Reber P; Furlan M; Beck EA; Finazzi G; Buelli M; Barbui T
    Thromb Haemost; 1985 Aug; 54(2):390-3. PubMed ID: 4082078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency.
    Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C
    Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen New Orleans: hereditary dysfibrinogenemia with an A alpha chain abnormality.
    Andes WA; Chavin SI; Beltran G; Stuckey WJ
    Thromb Res; 1982 Jan 1-15; 25(1-2):41-50. PubMed ID: 6801812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release.
    Lane DA; Cuddigan B; VanRoss M; Kakkar VV
    Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine.
    Yoshida N; Wada H; Morita K; Hirata H; Matsuda M; Yamazumi K; Asakura S; Shirakawa S
    Blood; 1991 May; 77(9):1958-63. PubMed ID: 2018836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Bondy: a new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules.
    Jandrot-Perrus M; Aurousseau MH; Rabiet MJ; Josso F
    Thromb Res; 1982 Sep; 27(6):659-70. PubMed ID: 6217586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A.
    Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y
    Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B:b interactions are essential for polymerization of variant fibrinogens with impaired holes 'a'.
    Okumura N; Terasawa F; Haneishi A; Fujihara N; Hirota-Kawadobora M; Yamauchi K; Ota H; Lord ST
    J Thromb Haemost; 2007 Dec; 5(12):2352-9. PubMed ID: 17922804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two cases of dysfibrinogenemia characterized by abnormal FPB release: fibrinogen Madrid I & II.
    Borrell M; Vila L; Solá J; Coll I; Gómez N; González N; Rutllant ML
    Thromb Res; 1987 Mar; 45(5):591-9. PubMed ID: 3109061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis.
    Ebert RF; Bell WR
    Proc Natl Acad Sci U S A; 1983 Dec; 80(23):7318-22. PubMed ID: 6580646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen kaiserslautern III: a new case of congenital dysfibrinogenemia with aalpha 16 arg-->cys substitution.
    Loreth RM; Meyer M; Albert FW
    Haemostasis; 2001; 31(1):12-7. PubMed ID: 11408744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release).
    Galanakis DK; Neerman-Arbez M; Kudryk B; Henschen A
    Blood Coagul Fibrinolysis; 2010 Mar; 21(2):135-9. PubMed ID: 20019599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen Chapel Hill II: defective in reactions with thrombin, factor XIIIa and plasmin.
    Carrell N; McDonagh J
    Br J Haematol; 1982 Sep; 52(1):35-47. PubMed ID: 6126210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen Houston: a dysfibrinogen exhibiting defective fibrin monomer aggregation and alpha-chain cross-linkages.
    Weinger RS; Rudy C; Moake JL; Conlon CL; Cimo PL
    Am J Hematol; 1980; 9(3):237-48. PubMed ID: 6165239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.